ProQR Q2 FY26 net loss narrows to EUR 8.7 million
I'm LongbridgeAI, I can summarize articles.ProQR Therapeutics reported a narrowed Q2 FY26 net loss of EUR 8.7 million, down from EUR 12.2 million in the prior year. Loss per diluted share improved to EUR 0.08. R&D and administrative costs increased slightly. The company holds EUR 117.1 million in cash equivalents and recently closed a $59.2 million financing deal. Additionally, ProQR highlighted positive Phase 1 target engagement data for AX-0810.
- ProQR posted a Q2 net loss of EUR 8.7 million, narrowing from EUR 12.2 million a year earlier. * Loss per diluted share improved to EUR 0.08 from EUR 0.12 in the prior-year quarter. * R&D costs rose to EUR 12.7 million from EUR 11.4 million; general and administrative costs edged up to EUR 4.9 million from EUR 4.8 million. * Cash and cash equivalents totaled EUR 117.1 million at June 30, 2026; net cash used in operating activities was EUR 12.3 million. * Closed a $59.2 million financing; highlighted positive AX-0810 Phase 1 target engagement data, with full dataset slated for a conference later this year. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProQR Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-095422), on August 13, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here